Zofran Lawsuit Surge Brings Discussion Of Birth Defect Report Tracking By Centers For Disease Control

February 29, 2016 – – ZofranLegal.com reports on recent news indicating that the Centers for Disease Control have been tracking birth defect reports. Though this tracking has been going on for some time, it has once again gained public attention due to a recent surge in Zika cases and Zofran lawsuits. Zofran lawsuits filed in federal courts from across the U.S. have been formed into multidistrict litigation number 2657 and are steadily moving forward as their numbers continue to increase. The most recent case number reports have placed lawsuit numbers over 200.

According to recently released information, the Centers for Disease Control has a system in place in 41 states across America. Although the actual tracking process has been questioned by some, and has been noted as flawed by others, the intent of their birth defect tracking is an important one: to monitor which birth defects are increasing or decreasing, to identify and investigate possible causes of these defects, to create increased public awareness of risk factors in order to better prevent birth defects, and assist those currently living with defects so that they are able to find proper help.

Those who have filed Zofran birth defect lawsuits are reportedly questioning whether the CDC’s tracking system could help them to illustrate what other studies have reported as well: that fetal exposure to Zofran while developing in utero places babies at increased risk for the development of a range of serious and sometimes fatal birth defects. They all commonly claim that, due to Zofran exposure, children have been born with cleft lip and palate, clubfoot, respiratory distress syndrome, transposition of the greater vessels, atrial septal and ventricular septal defect, and kidney defects. On many occasions, parents involved in the lawsuits have tragically had their children pass away due to fatal defects.

The plaintiffs in Zofran lawsuits have filed their complaints against Zofran manufacturer GlaxoSmithKline and all are questioning the same marketing move by the company, when, despite having no FDA-approval to do so, they marketed the drug to pregnant women as a treatment for morning sickness. This was done without safety testing on expectant mothers or their unborn babies and this “off-label” marketing is a true point of contention today.

While those involved anxiously await trial, the attorneys of Monheit Law are working to assist anyone else who may have been a victim. Mothers who took Zofran while pregnant and who later gave birth to infants with defects, may be entitled to substantial compensation. At this time, Monheit Law is offering free legal consultations for those affected who may be looking to pursue justice.

To request additional Zofran birth defect information, or to ask questions, please contact Michael Monheit of Monheit Law by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60008420